Press Release: Dupixent® (dupilumab) Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis (EoE)

Nitesh sinha October 22, 2023
https://ift.tt/JzVhxu4

Dupixent® (dupilumab) Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis (EoE)



from Sanofi - Aventis Groupe https://ift.tt/Bs10RSb
via IFTTT
Tags:
Nitesh sinha

Posted by: Nitesh sinha

Post a Comment

0 Comments

Please ,
Do not enter any kind of span link